The biotech industry is currently facing a paradigm shift in which pivotal trials, which traditionally address regulatory requirements, must also address critical commercial goals that include persuasive data to satisfy the payor. At Melinta Therapeutics, commercial needs — particularly payor needs — play a major voice in its R&D strategy.
Melinta Therapeutics’ mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. Its late-stage investigational antibiotic, delafloxacin, is currently in Phase 3 development for acute bacterial skin and skin structure infections. In addition, Melinta’s RX‑04 research program is yielding new classes of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause serious hospital infections.
- Yale’s Dr. Thomas Steitz, co-founder of Melinta, will provide introductory remarks about the the company’s foundation science.
- Mary Szela, CEO of Melinta, and Eugene Sun, Senior Vice President of R&D, will talk through the Melinta process, indicating what worked and what didn’t, and illustrating why taking a strategic and measured approach to embedding payor needs into the R&D process ensures long-term success for your company and for your lead assets.